



Most men with erectile dysfunction have concomitant comorbidities. Valiquette and colleagues review the reliability, efficacy and safety of vardenafil in these patients with comorbidities such as hypertension, dyslipidemia and diabetes. See page 187 for details on this study and the results.

La plupart des hommes qui vivent de la dysfonction érectile présentent des comorbidités concomitantes. Valiquette et ses collaborateurs ont passé en revue la fiabilité, l'efficacité et la sécurité du vardenafil chez les patients présentant des comorbidités, telles que l'hypertension, la dyslipidémie et le diabète. Veuillez vous référer à la page 187 pour connaître les détails de cette étude et les résultats.

Publications Mail Agreement no. 41387051. Return undeliverable Canadian copies to *CUAJ*, 1155 University, Suite 1155, Montréal QC H3B 3A7; journal@cua.org.

Numéro de convention poste-publications 41387051. Retourner toutes copies canadiennes non livrées au *JAUC*, 1155 rue Université, Bureau 1155, Montréal, QC H3B 3A7; journal@cua.org.

EDITORIAL

Indexation: not quite yet

L. Klotz

ÉDITORIAL

Indexation en cours

L. Klotz

CUA NEWS

Moving forward

J.B. Metcalfe

NOUVELLES DE L'AUC

Pistes d'avenir

J.B. Metcalfe

CONSENSUS GUIDELINE

Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement

Canadian Kidney Cancer Forum 2008

COMMENTARY

Canadian Kidney Cancer Forum 2008

M.A.S. Jewett, J.J. Knox, C. Kollmansberger, J. Basiuk

ORIGINAL RESEARCH

Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction — RELY-II

L. Valiquette, F. Montorsi, S. Auerbach; for the Vardenafil Study Group

COMMENTARY

Not perfect, but good enough

G. Brock

ORIGINAL RESEARCH

Recommendations by Canadian urologists and radiation oncologists for the treatment of clinically localized prostate cancer

A. Pearce, C. Newcomb, S. Husain

COMMENTARY

Urologists and radiation oncologists: working together for patient care

J. Chin

169

171

173

174

175

183

187

196

197

204

Detrol LA
 tolterodine L-tartrate extended-release capsules

Pfizer
 Working for a healthier world™
 DETROL LA® Pfizer Enterprises SARL, owner / Pfizer Canada Inc., licensee.™
 Pfizer Inc., used under license.
 © 2008, Pfizer Canada Inc., Kirkland, Quebec H9J 2M5

DETROL LA is indicated for the symptomatic management of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence, or any combination of these symptoms. Product Monograph available on request.

Member
 R&D PAB

ORIGINAL RESEARCH

- Competence in pediatric urology upon graduation from residency: perceptions of residents, program directors and pediatric urologists** 205
J.J. Mickelson, A.E. MacNeily, D. Samarasekera, D. Beiko, K. Afshar

COMMENTARY

- Pediatric procedures in urology residency training: finding the balance between relevant and attainable competency** 211
K. Psooy

REVIEW

- Biomarkers for detection and surveillance of bladder cancer** 212
L.I. Budman, W. Kassouf, J.R. Steinberg

POINT / COUNTERPOINT

- Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?; Rebuttal** 222; 228
S. North

- Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer; Rebuttal** 225; 229
A. So

CASE REPORT

- Clear cell myomelanocytic tumour: minimally invasive treatment of a rare bladder tumour** 230
M.L. Pianezza, J. Slatnik, H.J. Evans

MEETING ABSTRACTS

- 63rd Annual Meeting of the Canadian Urological Association June 22–25 2008, Shaw Convention Centre, Edmonton** 243

IN MEMORIAM

352

RESOURCES

- Calendar** 221
Classified Advertising 235
Instructions for Authors 237
Instructions aux auteurs 238
Prescribing Index 345

ADVERTISERS' INDEX / INDEX DES ANNONCEURS

AMS Canada Inc.
Inside back cover

AstraZeneca Canada Inc.
Zoladex 162, 345

Astellas Pharma Canada, Inc.
Vesicare 164, 346-7

Clarion Medical Technologies Inc.
172

GlaxoSmithKline
Avodart 166-7, 348-9

Merck Frosst Canada Ltd.
Proscar 184-5, 350-1

Olympus Canada Inc.
Inside front cover

Pfizer Canada Inc.
Detrol LA 161
Sutent Outside back cover

All editorial matter in *CUAJ* represents the opinions of the authors and not necessarily those of the Canadian Urological Association. The CUA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CUAJ*.



EDITOR-IN-CHIEF RÉDACTEUR EN CHEF

Laurence H. Klotz, MD, FRCSC
Toronto, ON

SECTION EDITORS CHEFS DES RUBRIQUES

Prostate Cancer

Armen Aprikian, MD, FRCSC
Montréal, QC

Erectile Dysfunction

Gerald B. Brock, MD, FRCSC
London, ON

Bladder Cancer

Yves Fradet, MD, FRCSC
Québec, QC

Incontinence

Jerzy B. Gajewski, MD, FRCSC
Halifax, NS

Neuro-Urology/Reconstruction

Sender Herschorn, BSc, MDCM, FRCSC
Toronto, ON

Infertility

Keith A. Jarvi, MD, FRCSC
Toronto, ON

Kidney Cancer

Michael Jewett, MD, FRCSC
Toronto, ON

Clinical Epidemiology

Pierre Karakiewicz, MD, FRCSC
Montréal, QC

Minimally Invasive Surgery/ Image Guided Therapy

Patrick Luke, MD, FRCSC
London, ON

Pediatric Urology

Andrew E. MacNeily, MD, FRCSC, FAAP
Vancouver, BC

Infectious Disease and Prostatitis

J. Curtis Nickel, MD, FRCSC
Kingston, ON

Community Urology

R. Ian Reid, MD, FRCSC
Charlottetown, PEI

Testis and Penile Cancer

Robert Siemens, MD, FRCSC
Kingston, ON

CONSULTING EDITORS ÉDITEURS-CONSEIL

Serge Carrier, MD, FRCSC
Montréal, QC

Richard W. Casey, HBSc, MD, FRCSC
Oakville, ON

Michael Chetner, MD, FRCSC
Edmonton, AB

Joseph L. Chin, MD, FRCSC
London, ON

Jacques A. Corcos, MD, FRCSC
Montréal, QC

John D. Denstedt, MD, FRCSC
London, ON

Mostafa M. Elhilali, MD, PhD, FRCSC
Montréal, QC

Neil Fleshner, MD, MPH, FRCSC
Toronto, ON

Ronald Gerritzen, MD, FRCSC, FACS
Ottawa, ON

Martin E. Gleave, MD, FRCSC, FACS
Vancouver, BC

Larry Goldenberg, OBC, MD, FRCSC, FACS
Vancouver, BC

Mireille Grégoire, MD, FRCSC
Québec, QC

Anil Kapoor, MD, DABU, FRCSC
Hamilton, ON

Louis Lacombe, MD, FRCSC
Québec, QC

Michael P. Leonard, MD, FRCSC, FAAP
Ottawa, ON

Ronald B. Moore, MD, PhD, FRCSC, FACS
Edmonton, AB

Richard W. Norman, MD, FRCSC
Halifax, NS

Kenneth Pace, MD, MSc, FRCSC
Toronto, ON

Hassan A. Razvi, MD, FRCSC
London, ON

Fred Saad, MD, FRCS
Montréal, QC

M. Lynn Stothers, MD, MHSc, FRCSC
Vancouver, BC

John Trachtenberg, MD, FRCSC, FACS
Toronto, ON

Luc Valiquette, MD, FRCSC, FACS

Montréal, QC

James W.L. Wilson, MD, FRCSC

Kingston, ON

Tim A. Wollin, MD, FRCSC, MSc
Edmonton, AB

EDITORIAL STAFF ÉQUIPE RÉDACTIONNELLE

Managing Editor

Directrice de la rédaction

Josephine Sciortino, MA
josephine.sciortino@cua.org
514 395-0376
fax 514 875-0205

Graphic Designer • Graphiste

Marie-Pierre Goudreau

Translator • Traductrice

Véronique Pied

CANADIAN UROLOGICAL ASSOCIATION • ASSOCIATION DES UROLOGUES DU CANADA

CUA President

Président, AUC

James B. Metcalfe, MD, FRCSC

MARKETING AND ADVERTISING SALES • MARKETING ET PUBLICITÉ

Keith Communications Inc.

info@keithhealthcare.com

Toronto:

800 661-5004; 905 278-6700;

fax 905 278-4850

Montréal:

877 761-0447; 514 624-6979;

fax 514 624-6707

CUAJ-JAUC is owned by the Canadian Urological Association.

All prescription drug advertisements have been cleared by the Pharmaceutical Advertising Advisory Board (PAAB).



Printed by Dolco Printing, Ottawa, Ont. Appears in February, April, June, August, October and December.

La revue est imprimée par Dolco Printing, Ottawa (Ontario). Elle paraît en février, avril, juin, août, octobre et décembre.

© 2008 Canadian Urological Association. For subscription, permissions and other service information, email the journal office at journal@cua.org.

ASSOCIATION MÉDICALE CANADIENNE  CANADIAN MEDICAL ASSOCIATION

Published by the Canadian Medical Association

Editorial Coordinators Coordonnatrices de la rédaction

Kate Brown

kate.brown@cma.ca

800 663-7336 x2406

Melanie Slavitch

melanie.slavitch@cma.ca

800 663-7336 x2182

fax 613 565-5471

Advertising Publicitaires

Beverly Kirkpatrick

Deborah Woodman

Online Publishing Publication en direct

Holly Bodger

James Manship

Shirley Waddell

Director, Publications

Directrice, services d'édition

Glenda Proctor

Editors

Rédactrices

Melinda Hodgins

melinda.hodgins@cma.ca

800 663-7336 x2198

Molly Meitin

molly.meitin@cma.ca

800 663-7336 x2114

fax 613 565-5471

Production

Kathryn A. Freamo

Nicole Barbeau

Carole Lalonde

Clara Walker